Cynthia Levy
University of Miami
Internal medicineIntensive care medicinePlaceboPrimary (chemistry)Obeticholic acidLiver diseaseAutoimmune hepatitisCirrhosisInflammatory bowel diseaseMEDLINELiver transplantationPrimary biliary cirrhosisPrimary sclerosing cholangitisUrsodeoxycholic acidPopulationIn patientHepatologyMedicineCohortGastroenterology
165Publications
27H-index
1,634Citations
Publications 217
Newest
#1Guilherme Grossi Lopes Cançado (UFMG: Universidade Federal de Minas Gerais)H-Index: 8
#2Michelle Harriz Braga (USP: University of São Paulo)H-Index: 1
Last. Elze Maria Gomes Oliveira (University of Lusaka)H-Index: 1
view all 25 authors...
Introduction and objectives null Little is known about primary biliary cholangitis (PBC) in non-whites. The purpose of this study was to evaluate clinical features and outcomes of PBC in a highly admixed population. null Material and methods null The Brazilian Cholestasis Study Group multicentre database was reviewed to assess demographics, clinical features and treatment outcomes of Brazilian patients with PBC. null Results null 562 patients (95% females, mean age 51±11 years) with PBC were inc...
Source
#1Binu V. John (Veterans Health Administration)H-Index: 3
#2Bassam Dahman (VCU: Virginia Commonwealth University)H-Index: 22
Last. Cynthia Levy (UM: University of Miami)H-Index: 27
view all 7 authors...
Background null The natural history of patients with anti-mitochondrial antibody (AMA)-negative Primary Biliary Cholangitis (PBC) cirrhosis has not been well defined, with prior studies showing discordant results. Furthermore, most studies of AMA-negative PBC have limited numbers of patients with cirrhosis and liver-related outcomes. null Methods null We investigated the association of AMA-negative PBC and the development of death, liver-related death, decompensation and hepatocellular carcinoma...
Source
Source
#1Raj Vuppalanchi (IU: Indiana University)H-Index: 45
#2Stephen H. Caldwell (UVA: University of Virginia)H-Index: 76
view all 14 authors...
ABSTRACT null Background & Aim null Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with dual agonistic properties (α/γ). Due to a strong mechanistic rationale, we aimed to test the safety and efficacy of saroglitazar in patients with primary biliary cholangitis (PBC) who were either ursodeoxycholic acid (UDCA) resistant or intolerant. null Methods null In this double-blind, phase 2 proof-of-concept trial, 37 PBC patients were randomized to saroglitazar 4 mg (n=...
Source
Source
Source
#1Andreas E Kremer (FAU: University of Erlangen-Nuremberg)H-Index: 1
BACKGROUND & AIMS Primary biliary cholangitis (PBC) can result in life-altering cholestatic pruritus and fatigue, but treatment options are limited. Seladelpar, a peroxisome proliferator-activated receptor-delta (PPARδ) agonist, has demonstrated potent anti-cholestatic effects in clinical studies. This open-label, uncontrolled phase 2 study in PBC patients evaluated the effects of 1-year of seladelpar treatment on measures of pruritus and quality of life. METHODS Self-reported experiences of 101...
Source
#1Keith D. Lindor (UC Davis: University of California, Davis)H-Index: 1
#2Christopher L. Bowlus (UC Davis: University of California, Davis)H-Index: 61
Last. Marlyn J. Mayo (UTSW: University of Texas Southwestern Medical Center)H-Index: 29
view all 5 authors...
In May 2021, the FDA issued a new warning restricting the use of obeticholic acid in patients with advanced cirrhosis 1 . This is defined as cirrhosis with current or prior evidence of liver decompensation (e.g., encephalopathy, coagulopathy) or portal hypertension(e.g., ascites, gastroesophageal varices, or persistent thrombocytopenia).
Source
#1Binu V. John (UM: University of Miami)H-Index: 3
#2Kaley Schwartz (Veterans Health Administration)H-Index: 3
Last. David E. Kaplan (UPenn: University of Pennsylvania)H-Index: 73
view all 8 authors...
Source
#1Guilherme Grossi Lopes Cançado (UFMG: Universidade Federal de Minas Gerais)H-Index: 8
#2Michelle Harriz Braga (USP: University of São Paulo)H-Index: 1
Last. Elze Maria Gomes Oliveira (University of Lusaka)H-Index: 1
view all 25 authors...
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease in which anti-mitochondrial antibodies (AMA) are the diagnostic hallmark. Whether AMA-negative PBC patients represent a different phenotype of disease is highly debated. The purpose of our study was to compare AMA-positive and AMA-negative PBC patients in a large non-white admixed Brazilian cohort. The Brazilian Cholestasis Study Group multicentre database was reviewed to assess demographics, clinical features and treatment...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.